ReviewPharmaceuticals (Basel, Switzerland)2026
Mechanistic Networks, Cellular Specificity, and Therapeutic Opportunities of Ferroptosis in Ulcerative Colitis.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- Transcriptomic Analysis Reveals the Antioxidant and Anti-Inflammatory Mechanisms of EGCG-Zn Nanoparticles in Dextran Sulfate Sodium-Induced Colitis in Mice.Antioxidants (Basel, Switzerland) · 2026Article
- Quince Gel Attenuates Experimental Ulcerative Colitis Through Antioxidant, Anti-Inflammatory and Mucosal Repair Mechanisms: Integrated Histopathological, Bioinformatic and Molecular Docking Analyses.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by epithelial barrier disruption, oxidative stress, immune dysregulation, and defective mucosal healing. Recent studies have identified ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation, as a key mechanism linking these processes. This review summarizes the current progress in understanding the role of ferroptosis in colitis. Available evidence shows that ferroptosis occurs in both human UC and experimental colitis models, with intestinal epithelial cells representing the best-established target compartment. Recent studies have further expanded this concept to reparative immune cells, particularly type 2 (M2) macrophages, thereby indicating that ferroptosis contributes not only to barrier injury but also to impaired mucosal healing. Mechanistically, colitis-associated ferroptosis is governed by interconnected networks involving solute carrier family 7 member 11 (SLC7A11)/glutathione (GSH)/glutathione peroxidase 4 (GPX4) failure, acyl-CoA synthetase long chain family member 4 (ACSL4)-dependent lipid remodeling, iron overload, mitochondrial reactive oxygen species (ROS) amplification, inflammatory signaling, and N6-methyladenosine (m6A)-mediated post-transcriptional regulation. In parallel, microbiota-derived metabolites and dietary factors can either suppress or exacerbate ferroptotic injury. Therapeutically, ferroptosis-targeted strategies, including iron chelation, nutrient-based interventions, natural products, exosomes, and nanoplatforms show promising preclinical efficacy. Overall, ferroptosis provides a connected framework for understanding colitis pathogenesis and provides new opportunities for biomarker development and mechanism-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.